Revolution Medicines to Participate in March 2025 Investor Conferences
Revolution Medicines (Nasdaq: RVMD), a late-stage clinical oncology company focused on developing targeted therapies for RAS-addicted cancers, has announced its participation in three major investor conferences in March 2025.
The company's CEO and chairman, Mark A. Goldsmith, M.D., Ph.D., will participate in fireside chats at:
- TD Cowen 45th Annual Healthcare Conference on March 3 at 1:50 p.m. ET
- Barclays 27th Annual Global Healthcare Conference on March 11 at 8:00 a.m. ET
- 2025 Leerink Partners Global Healthcare Conference on March 12 at 2:20 p.m. ET
Live webcasts of these events will be available on the company's investor relations website, with replays accessible for at least 14 days following the presentations.
Revolution Medicines (Nasdaq: RVMD), un'azienda clinica oncologica in fase avanzata focalizzata nello sviluppo di terapie mirate per tumori dipendenti da RAS, ha annunciato la sua partecipazione a tre importanti conferenze per investitori a marzo 2025.
Il CEO e presidente dell'azienda, Mark A. Goldsmith, M.D., Ph.D., parteciperà a discussioni informali presso:
- TD Cowen 45ª Conferenza Annuale sulla Salute il 3 marzo alle 13:50 ET
- Barclays 27ª Conferenza Globale Annuale sulla Salute l'11 marzo alle 8:00 ET
- 2025 Leerink Partners Conferenza Globale sulla Salute il 12 marzo alle 14:20 ET
Le dirette streaming di questi eventi saranno disponibili sul sito web delle relazioni con gli investitori dell'azienda, con le registrazioni accessibili per almeno 14 giorni dopo le presentazioni.
Revolution Medicines (Nasdaq: RVMD), una empresa clínica oncológica en etapa avanzada centrada en el desarrollo de terapias dirigidas para cánceres adictos a RAS, ha anunciado su participación en tres importantes conferencias de inversores en marzo de 2025.
El CEO y presidente de la empresa, Mark A. Goldsmith, M.D., Ph.D., participará en charlas informales en:
- TD Cowen 45ª Conferencia Anual de Salud el 3 de marzo a la 1:50 p.m. ET
- Barclays 27ª Conferencia Global Anual de Salud el 11 de marzo a las 8:00 a.m. ET
- 2025 Leerink Partners Conferencia Global de Salud el 12 de marzo a las 2:20 p.m. ET
Las transmisiones en vivo de estos eventos estarán disponibles en el sitio web de relaciones con inversores de la empresa, con repeticiones accesibles durante al menos 14 días después de las presentaciones.
Revolution Medicines (Nasdaq: RVMD), RAS 의존성 암을 위한 표적 치료제를 개발하는 데 집중하는 후기 단계 임상 종양학 회사가 2025년 3월에 열리는 세 가지 주요 투자자 회의에 참여한다고 발표했습니다.
회사의 CEO이자 회장인 Mark A. Goldsmith, M.D., Ph.D.는 다음과 같은 비공식 대화에 참여할 예정입니다:
- TD Cowen 제45회 연례 헬스케어 회의: 3월 3일 오후 1시 50분 ET
- Barclays 제27회 연례 글로벌 헬스케어 회의: 3월 11일 오전 8시 ET
- 2025 Leerink Partners 글로벌 헬스케어 회의: 3월 12일 오후 2시 20분 ET
이 이벤트의 생중계는 회사의 투자자 관계 웹사이트에서 제공되며, 프레젠테이션 후 최소 14일 동안 다시 볼 수 있습니다.
Revolution Medicines (Nasdaq: RVMD), une entreprise clinique d'oncologie en phase avancée axée sur le développement de thérapies ciblées pour les cancers dépendants de RAS, a annoncé sa participation à trois grandes conférences pour investisseurs en mars 2025.
Le PDG et président de l'entreprise, Mark A. Goldsmith, M.D., Ph.D., participera à des discussions informelles lors des événements suivants :
- TD Cowen 45e Conférence Annuelle de Santé le 3 mars à 13h50 ET
- Barclays 27e Conférence Globale Annuelle de Santé le 11 mars à 8h00 ET
- 2025 Leerink Partners Conférence Globale de Santé le 12 mars à 14h20 ET
Les webcasts en direct de ces événements seront disponibles sur le site web des relations investisseurs de l'entreprise, avec des rediffusions accessibles pendant au moins 14 jours après les présentations.
Revolution Medicines (Nasdaq: RVMD), ein klinisches Onkologieunternehmen in der späten Phase, das sich auf die Entwicklung zielgerichteter Therapien für RAS-abhängige Krebserkrankungen konzentriert, hat seine Teilnahme an drei wichtigen Investorenkonferenzen im März 2025 angekündigt.
Der CEO und Vorsitzende des Unternehmens, Mark A. Goldsmith, M.D., Ph.D., wird an informellen Gesprächen teilnehmen bei:
- TD Cowen 45. jährliche Gesundheitskonferenz am 3. März um 13:50 Uhr ET
- Barclays 27. jährliche globale Gesundheitskonferenz am 11. März um 8:00 Uhr ET
- 2025 Leerink Partners globale Gesundheitskonferenz am 12. März um 14:20 Uhr ET
Die Live-Webcasts dieser Veranstaltungen sind auf der Investor-Relations-Website des Unternehmens verfügbar, mit Wiederholungen, die mindestens 14 Tage nach den Präsentationen zugänglich sind.
- None.
- None.
REDWOOD CITY, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will participate in three upcoming investor conferences.
Details of the company’s participation are as follows:
- TD Cowen 45th Annual Healthcare Conference
- Fireside Chat Date/Time: Monday, March 3 at 1:50 p.m. ET
- Barclays 27th Annual Global Healthcare Conference
- Fireside Chat Date/Time: Tuesday, March 11 at 8:00 a.m. ET
- 2025 Leerink Partners Global Healthcare Conference
- Fireside Chat Date/Time: Wednesday, March 12 at 2:20 p.m. ET
To listen to a live webcast of any of these events, or access archived webcasts, please visit: https://ir.revmed.com/events-and-presentations. Following the live webcasts, replays will be available on the company’s website for at least 14 days.
About Revolution Medicines, Inc.
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are currently in clinical development. Additional development opportunities in the company’s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-5127 (G12V), RMC-0708 (Q61H) and RMC-8839 (G13C). For more information, please visit www.revmed.com and follow us on LinkedIn.
Revolution Medicines Media & Investor Contact:
media@revmed.com
investors@revmed.com
FAQ
When is Revolution Medicines (RVMD) presenting at the TD Cowen Healthcare Conference in March 2025?
What investor conferences is RVMD attending in March 2025?
How long will RVMD's conference webcasts be available for replay?
What type of cancer treatments is Revolution Medicines (RVMD) developing?
Where can investors access RVMD's March 2025 conference webcasts?
